Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. Bekkering, G. E., Agoritsas, T., Lytvyn, L., Heen, A. F., Feller, M., Moutzouri, E., Abdulazeem, H., Aertgeerts, B., Beecher, D., Brito, J. P., Farhoumand, P. D., Ospina, N. S., Rodondi, N., Driel, M. v., Wallace, E., Snel, M., Okwen, P. M., Siemieniuk, R., Vandvik, P. O., Kuijpers, T., & Vermandere, M. BMJ, May, 2019. Publisher: British Medical Journal Publishing Group Section: Practice![Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Clinical question What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice. Current practice Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels \textgreater10 mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing. Recommendation The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH \textgreater20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old). How this guideline was created A guideline panel including patients, clinicians, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach. The evidence The systematic review included 21 trials with 2192 participants. For adults with SCH, thyroid hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid related symptoms, including depressive symptoms, fatigue, and body mass index (moderate to high quality evidence). Thyroid hormones may have little or no effect on cardiovascular events or mortality (low quality evidence), but harms were measured in only one trial with few events at two years’ follow-up. Understanding the recommendation The panel concluded that almost all adults with SCH would not benefit from treatment with thyroid hormones. Other factors in the strong recommendation include the burden of lifelong management and uncertainty on potential harms. Instead, clinicians should monitor the progression or resolution of the thyroid dysfunction in these adults. Recommendations are made actionable for clinicians and their patients through visual overviews. These provide the relative and absolute benefits and harms of thyroid hormones in multilayered evidence summaries and decision aids available in MAGIC (https://app.magicapp.org/) to support shared decisions and adaptation of this guideline.
@article{bekkering_thyroid_2019,
title = {Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline},
volume = {365},
copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions},
issn = {0959-8138, 1756-1833},
shorttitle = {Thyroid hormones treatment for subclinical hypothyroidism},
url = {https://www.bmj.com/content/365/bmj.l2006},
doi = {10.1136/bmj.l2006},
abstract = {Clinical question What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice.
Current practice Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels {\textgreater}10 mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing.
Recommendation The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH {\textgreater}20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old).
How this guideline was created A guideline panel including patients, clinicians, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach.
The evidence The systematic review included 21 trials with 2192 participants. For adults with SCH, thyroid hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid related symptoms, including depressive symptoms, fatigue, and body mass index (moderate to high quality evidence). Thyroid hormones may have little or no effect on cardiovascular events or mortality (low quality evidence), but harms were measured in only one trial with few events at two years’ follow-up.
Understanding the recommendation The panel concluded that almost all adults with SCH would not benefit from treatment with thyroid hormones. Other factors in the strong recommendation include the burden of lifelong management and uncertainty on potential harms. Instead, clinicians should monitor the progression or resolution of the thyroid dysfunction in these adults. Recommendations are made actionable for clinicians and their patients through visual overviews. These provide the relative and absolute benefits and harms of thyroid hormones in multilayered evidence summaries and decision aids available in MAGIC (https://app.magicapp.org/) to support shared decisions and adaptation of this guideline.},
language = {en},
urldate = {2020-03-27},
journal = {BMJ},
author = {Bekkering, G. E. and Agoritsas, T. and Lytvyn, L. and Heen, A. F. and Feller, M. and Moutzouri, E. and Abdulazeem, H. and Aertgeerts, B. and Beecher, D. and Brito, J. P. and Farhoumand, P. D. and Ospina, N. Singh and Rodondi, N. and Driel, M. van and Wallace, E. and Snel, M. and Okwen, P. M. and Siemieniuk, R. and Vandvik, P. O. and Kuijpers, T. and Vermandere, M.},
month = may,
year = {2019},
pmid = {31088853},
note = {Publisher: British Medical Journal Publishing Group
Section: Practice},
}
Downloads: 0
{"_id":"4echhmRR3LdrZFwtX","bibbaseid":"bekkering-agoritsas-lytvyn-heen-feller-moutzouri-abdulazeem-aertgeerts-etal-thyroidhormonestreatmentforsubclinicalhypothyroidismaclinicalpracticeguideline-2019","author_short":["Bekkering, G. E.","Agoritsas, T.","Lytvyn, L.","Heen, A. F.","Feller, M.","Moutzouri, E.","Abdulazeem, H.","Aertgeerts, B.","Beecher, D.","Brito, J. P.","Farhoumand, P. D.","Ospina, N. S.","Rodondi, N.","Driel, M. v.","Wallace, E.","Snel, M.","Okwen, P. M.","Siemieniuk, R.","Vandvik, P. O.","Kuijpers, T.","Vermandere, M."],"bibdata":{"bibtype":"article","type":"article","title":"Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline","volume":"365","copyright":"Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions","issn":"0959-8138, 1756-1833","shorttitle":"Thyroid hormones treatment for subclinical hypothyroidism","url":"https://www.bmj.com/content/365/bmj.l2006","doi":"10.1136/bmj.l2006","abstract":"Clinical question What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice. Current practice Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels \\textgreater10 mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing. Recommendation The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH \\textgreater20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old). How this guideline was created A guideline panel including patients, clinicians, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach. The evidence The systematic review included 21 trials with 2192 participants. For adults with SCH, thyroid hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid related symptoms, including depressive symptoms, fatigue, and body mass index (moderate to high quality evidence). Thyroid hormones may have little or no effect on cardiovascular events or mortality (low quality evidence), but harms were measured in only one trial with few events at two years’ follow-up. Understanding the recommendation The panel concluded that almost all adults with SCH would not benefit from treatment with thyroid hormones. Other factors in the strong recommendation include the burden of lifelong management and uncertainty on potential harms. Instead, clinicians should monitor the progression or resolution of the thyroid dysfunction in these adults. Recommendations are made actionable for clinicians and their patients through visual overviews. These provide the relative and absolute benefits and harms of thyroid hormones in multilayered evidence summaries and decision aids available in MAGIC (https://app.magicapp.org/) to support shared decisions and adaptation of this guideline.","language":"en","urldate":"2020-03-27","journal":"BMJ","author":[{"propositions":[],"lastnames":["Bekkering"],"firstnames":["G.","E."],"suffixes":[]},{"propositions":[],"lastnames":["Agoritsas"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Lytvyn"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Heen"],"firstnames":["A.","F."],"suffixes":[]},{"propositions":[],"lastnames":["Feller"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Moutzouri"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Abdulazeem"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Aertgeerts"],"firstnames":["B."],"suffixes":[]},{"propositions":[],"lastnames":["Beecher"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Brito"],"firstnames":["J.","P."],"suffixes":[]},{"propositions":[],"lastnames":["Farhoumand"],"firstnames":["P.","D."],"suffixes":[]},{"propositions":[],"lastnames":["Ospina"],"firstnames":["N.","Singh"],"suffixes":[]},{"propositions":[],"lastnames":["Rodondi"],"firstnames":["N."],"suffixes":[]},{"propositions":[],"lastnames":["Driel"],"firstnames":["M.","van"],"suffixes":[]},{"propositions":[],"lastnames":["Wallace"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Snel"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Okwen"],"firstnames":["P.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Siemieniuk"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Vandvik"],"firstnames":["P.","O."],"suffixes":[]},{"propositions":[],"lastnames":["Kuijpers"],"firstnames":["T."],"suffixes":[]},{"propositions":[],"lastnames":["Vermandere"],"firstnames":["M."],"suffixes":[]}],"month":"May","year":"2019","pmid":"31088853","note":"Publisher: British Medical Journal Publishing Group Section: Practice","bibtex":"@article{bekkering_thyroid_2019,\n\ttitle = {Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline},\n\tvolume = {365},\n\tcopyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions},\n\tissn = {0959-8138, 1756-1833},\n\tshorttitle = {Thyroid hormones treatment for subclinical hypothyroidism},\n\turl = {https://www.bmj.com/content/365/bmj.l2006},\n\tdoi = {10.1136/bmj.l2006},\n\tabstract = {Clinical question What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism (SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could alter practice.\nCurrent practice Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating hormone (TSH) levels {\\textgreater}10 mIU/L and for people with lower TSH values who are young, symptomatic, or have specific indications for prescribing.\nRecommendation The guideline panel issues a strong recommendation against thyroid hormones in adults with SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to become pregnant or patients with TSH {\\textgreater}20 mIU/L. It may not apply to patients with severe symptoms or young adults (such as those ≤30 years old).\nHow this guideline was created A guideline panel including patients, clinicians, and methodologists produced this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach.\nThe evidence The systematic review included 21 trials with 2192 participants. For adults with SCH, thyroid hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid related symptoms, including depressive symptoms, fatigue, and body mass index (moderate to high quality evidence). Thyroid hormones may have little or no effect on cardiovascular events or mortality (low quality evidence), but harms were measured in only one trial with few events at two years’ follow-up.\nUnderstanding the recommendation The panel concluded that almost all adults with SCH would not benefit from treatment with thyroid hormones. Other factors in the strong recommendation include the burden of lifelong management and uncertainty on potential harms. Instead, clinicians should monitor the progression or resolution of the thyroid dysfunction in these adults. Recommendations are made actionable for clinicians and their patients through visual overviews. These provide the relative and absolute benefits and harms of thyroid hormones in multilayered evidence summaries and decision aids available in MAGIC (https://app.magicapp.org/) to support shared decisions and adaptation of this guideline.},\n\tlanguage = {en},\n\turldate = {2020-03-27},\n\tjournal = {BMJ},\n\tauthor = {Bekkering, G. E. and Agoritsas, T. and Lytvyn, L. and Heen, A. F. and Feller, M. and Moutzouri, E. and Abdulazeem, H. and Aertgeerts, B. and Beecher, D. and Brito, J. P. and Farhoumand, P. D. and Ospina, N. Singh and Rodondi, N. and Driel, M. van and Wallace, E. and Snel, M. and Okwen, P. M. and Siemieniuk, R. and Vandvik, P. O. and Kuijpers, T. and Vermandere, M.},\n\tmonth = may,\n\tyear = {2019},\n\tpmid = {31088853},\n\tnote = {Publisher: British Medical Journal Publishing Group\nSection: Practice},\n}\n\n","author_short":["Bekkering, G. E.","Agoritsas, T.","Lytvyn, L.","Heen, A. F.","Feller, M.","Moutzouri, E.","Abdulazeem, H.","Aertgeerts, B.","Beecher, D.","Brito, J. P.","Farhoumand, P. D.","Ospina, N. S.","Rodondi, N.","Driel, M. v.","Wallace, E.","Snel, M.","Okwen, P. M.","Siemieniuk, R.","Vandvik, P. O.","Kuijpers, T.","Vermandere, M."],"key":"bekkering_thyroid_2019","id":"bekkering_thyroid_2019","bibbaseid":"bekkering-agoritsas-lytvyn-heen-feller-moutzouri-abdulazeem-aertgeerts-etal-thyroidhormonestreatmentforsubclinicalhypothyroidismaclinicalpracticeguideline-2019","role":"author","urls":{"Paper":"https://www.bmj.com/content/365/bmj.l2006"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/ckelleyt","dataSources":["W5PhLT7vuF6ko8d7J","tTydwtpFKyvDpy8qn"],"keywords":[],"search_terms":["thyroid","hormones","treatment","subclinical","hypothyroidism","clinical","practice","guideline","bekkering","agoritsas","lytvyn","heen","feller","moutzouri","abdulazeem","aertgeerts","beecher","brito","farhoumand","ospina","rodondi","driel","wallace","snel","okwen","siemieniuk","vandvik","kuijpers","vermandere"],"title":"Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline","year":2019}